Cellular Biomedicine Group Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 16 Posts
Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services
Article By: ChinaBio® Today Sunday, January 20, 2019 10:38 AM EST
MabPlex, a biologics CDMO, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital. MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics.
In this article: AZN, IRWD, CBMG, BGNE
Read
Week In Review: China Life Science Starts Off 2019 With $425 Million In Deals
Article By: ChinaBio® Today Sunday, January 13, 2019 1:18 PM EST
China's life science sector started off 2019 with $425 million from ten deals involving Apollomics, Schrödinger of New York City and BrightGene Bio-Medical of Suzhou, among others.
In this article: NVS, SPRO, CBMG, BHVN, ASLN
Read
Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion
Article By: ChinaBio® Today Saturday, October 6, 2018 5:57 PM EST
Shanghai Fosun Pharma announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary The company was established to develop mAb biosimilar drugs, bio-betters and novel mAbs.
In this article: GILD, CBMG
Read
Week In Review: Agilent Pays $250 Million To Acquire ACEA And Its Cell Therapy Analyzer
Article By: ChinaBio® Today Saturday, September 29, 2018 4:11 PM EST
ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhzou, will be acquired by Agilent for $250 million in cash. ACEA developed the xCELLigence® cell therapy analysis device used by academic and biopharma researchers.
In this article: A, VSTM, NVS, CBMG, TTPH
Read
Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center
Article By: ChinaBio® Today Saturday, March 24, 2018 5:53 PM EST
James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area.
In this article: ROG, AVH, NVS, CASI, CBMG, DOVA
Read
Week IReview: Tsinghua University Invests $276 Million ICambridge UK Biohub
Article By: ChinaBio® Today Saturday, February 10, 2018 4:38 PM EST
Tsinghua University Holdings of Beijing will invest $276 million to build a new biohub in the UK's Cambridge Science Park. The biohub will be a joint venture between TUS and Trinity College, Cambridge, the owner of the park.
In this article: RNN, CELG, BGNE, PFE, ARQL, CBMG
Read
Week In Review: 2017 Was Record Investment Year For China Life Science; Final Week Adds $669 Million
Article By: ChinaBio® Today Saturday, December 30, 2017 4:42 PM EST
Shanghai's SARI will pay $359 million to acquire a 90% interest in Group NMS, a Milan oncology biopharma. SARI is a biopharma investment firm affiliated with the Chinese Academy of Science research organization with the same name.
In this article: NBY, CBMG, WBA
Read
Week In Review: China's Creat To Restructure $1.5 Billion Biotest Takeover
Article By: ChinaBio® Today Saturday, November 11, 2017 4:17 PM EST
Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products company, because US regulators refused to approve the deal, worried a China corporation would have access to US donor information.
In this article: VRX, CBMG
Read
Premarket Biotech Digest – CBMG Inks New Deal, IPCI Sued, SYRS Gets FDA Nod
Article By: KKD Healthcare Analytics Tuesday, April 11, 2017 9:34 AM EST
Geron Corporation stock picked up on the news that the company has agreed to a settlement related to a consolidated class-action securities lawsuit. The company stock jumped over 19 percent in its previous trading session.
In this article: TXMD, GERN, IPCI, RPRX, GBLX, OMED, CBMG, SYRS
Read
Week In Review: Suzhou's Innovent Biologics Announces Record $260 Million Funding
Article By: ChinaBio® Today Saturday, December 3, 2016 12:30 PM EST
Innovent Biologics of Suzhou raised $260 million in a Series D round, a record venture funding for a China biopharma company. The round brings Innovent's total fundraising to $410 million.
In this article: PFE, ILMN, CBMG, LLY
Read
Week In Review: BeiGene Completes $158 Million IPO In The US
Article By: ChinaBio® Today Saturday, February 6, 2016 11:43 AM EST
The company priced the offering at the top of the expected range -- $24 per share -- and increased its size from 5.5 million ADSs to 6.6 million. In its first day of trading, the company's stock rose $4.62 to $28.62, a 19% increase.
In this article: SVA, CBMG, BGNE
Read
Week In Review: 3SBio To Stage $712 Million Hong Kong IPO
Article By: ChinaBio® Today Sunday, May 31, 2015 3:36 AM EST
3SBio, a China biopharma based in Shenyang, announced it will seek to raise up to $712 million in its Hong Kong IPO, scheduled for early June.
In this article: SCLN, CBMG, Q
Read
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Article By: The Life Sciences Report Monday, February 23, 2015 3:42 PM EST
Immuno-oncology took center stage in the drug development world in 2014. But can this preeminence continue in 2015? In this interview, Stephen Dunn of LifeTech Capital outlines how companies are leveraging these therapies, and where investors should look for opportunity in the sector.
In this article: MRK, BMY, RHHBY, ESRX, PFE, MKGAY, AZN, KITE, JUNO, NVS, DNDN, JNJ, AMGN, XON, ZIOP, CBMG
Read
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
Article By: ChinaBio® Today Sunday, February 15, 2015 10:44 AM EST
Deals, trials, financings and approvals in China healthcare sector this week.
In this article: CBMG, NEVPF, SHPHF, NVO, MRK, RPBIF, QGEN
Read
Provectus Biopharmaceuticals Concludes FDA Meeting For PV-10 Phase 3; Successful Completion Of AB Science's Futility Test For Masitinib
Article By: BioMedReports Tuesday, February 10, 2015 5:59 AM EST
Here is a look at some of the headlines for companies that made news in the healthcare sector on February 9, 2015.
In this article: ACHN, AKBS, AKR.L, AVXL, BIOC, BMRN, BSDM, CLDX, CBMG, CEMI, ENSG, GALE, ICUI, ISLT, IART, JUNO, LJPC, LFVN, MJNA, HTGC, NSPH, OREX, RDHL.TA, RCPT, RGLS, RNN, SBRA, WMGI, VBLT
Read
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Article By: BioMedReports Friday, January 16, 2015 3:44 AM EST
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI
Read
1 to 16 of 16 Posts